Scarica l'app Stockscreener
10.17
1.59%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Vir Biotech investors brace for earnings as losses shrink By Investing.com - Investing.com Canada
Vir Biotechnology Q1 2026 earnings preview - MSN
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology schedules CEO fireside chat at major healthcare event - Traders Union
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference - marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
Vir Biotechnology director Vicki Sato sells $221,025 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology director Vicki Sato sells $221,025 in stock - Investing.com
Vir Biotechnology (VIR) director sells 22,000 shares under 10b5-1 plan - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vir Biotechnology (VIR) CEO shifts 467,064 shares into family trust - Stock Titan
Vir Biotechnology | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Insider resale notice: Company (NASDAQ: VIR) plans common stock sales - Stock Titan
Vir Biotechnology prices $150M stock offering - MSN
[SCHEDULE 13G] Vir Biotechnology, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration - Yahoo Finance
Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Brii Bio reports durable HCB control in Phase II analysis - The Pharma Letter
Vir Biotechnology launches $200M public stock offering - MSN
Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com
Is VIR a Good Stock to Buy? - HarianBasis.co
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Certain Common Stock of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com
Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - 富途牛牛
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - The National Law Review
Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks
Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co
Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st
Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co
Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com Australia
Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - insidermonkey.com
Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey
8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey
Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a Potential 101% Upside in the Biotech Sector - DirectorsTalk Interviews
Vir Biotechnology, Inc. ($VIR) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Sanofi (SNY) Benefits from Vir Biotechnology's Collaboration wit - GuruFocus
Vir Biotechnology closes $240M Astellas deal for cancer drug By Investing.com - Investing.com Australia
Vir Biotechnology, Inc. Receives $240 Million Upfront Payment and $75 Million Equity Investment from Astellas - marketscreener.com
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatmen - PharmiWeb.com
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):